Aberrant Activation of AXL May Drive Progression of Squamous Cell Carcinoma in CLL Patients: a Mechanistic Study with Clinical Implications

Overview

Journal Br J Cancer

Specialty Oncology

Date 2024 Jun 17

PMID 38886556

Authors

Sutapa Sinha

Ray Guo

Miles D Del Busso

Weiguo Han

Justin Boysen

Linda E Wellik

Asish K Ghosh

Neil E Kay

Affiliations

Soon will be listed here.

Abstract

Background: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.

Methods: CLL cells and extracellular vesicles (EVs) from CLL patients' blood/plasma were purified and used. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

Results: We detected aberrant activation of AXL, AKT and ERK-1/2 in SCC cell lines compared to HEKa. We also detected increased expression of AXL in primary SCC tissues obtained from CLL patients. Increased activation of AXL, AKT, ERK-1/2 and Src was discernible in HEKa upon co-culturing with CLL cells. Further analysis suggests that Gas6, a ligand of AXL, regulates AXL activation in co-cultured HEKa. Interestingly, exposure of HEKa cells to CLL plasma-derived EVs induced expression of AXL, P-AKT, and EMT-associated markers leading to migration of the cells. Finally, pharmacologic inhibition of AXL induced cell death in SCC lines in a dose dependent manner.

Conclusions: Our findings that CLL cells likely are involved in driving SCC progression, at least in part, via activation of the AXL signaling axis, indicating that AXL inhibition may be beneficial for our CLL patients with SCC.

References

Gajiwala K, Grodsky N, Bolanos B, Feng J, Ferre R, Timofeevski S . The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. J Biol Chem. 2017; 292(38):15705-15716. PMC: 5612104. DOI: 10.1074/jbc.M116.771485. View

Mansfield A, Rabe K, Slager S, Schwager S, Call T, Brewer J . Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pract. 2013; 10(1):e1-4. PMC: 4500828. DOI: 10.1200/JOP.2013.000921. View

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J . Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013; 122(14):2443-52. DOI: 10.1182/blood-2013-03-491431. View

Boshuizen J, Koopman L, Krijgsman O, Shahrabi A, van den Heuvel E, Ligtenberg M . Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018; 24(2):203-212. DOI: 10.1038/nm.4472. View

Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D . Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma. 2019; 60(13):3204-3213. DOI: 10.1080/10428194.2019.1620941. View

Travis L, Curtis R, Hankey B, Fraumeni Jr J . Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992; 84(18):1422-7. DOI: 10.1093/jnci/84.18.1422. View

Velez N, Karia P, Vartanov A, Davids M, Brown J, Schmults C . Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014; 150(3):280-7. DOI: 10.1001/jamadermatol.2013.6249. View

Nyakas M, Fleten K, Haugen M, Engedal N, Sveen C, Farstad I . AXL inhibition improves BRAF-targeted treatment in melanoma. Sci Rep. 2022; 12(1):5076. PMC: 8948193. DOI: 10.1038/s41598-022-09078-z. View

Zhu C, Wei Y, Wei X . AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019; 18(1):153. PMC: 6827209. DOI: 10.1186/s12943-019-1090-3. View

10.

Green J, Ikram M, Vyas J, Patel N, Proby C, Ghali L . Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006; 94(10):1446-51. PMC: 2361292. DOI: 10.1038/sj.bjc.6603135. View

11.

Sinha S, Boysen J, Nelson M, Secreto C, Warner S, Bearss D . Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015; 21(9):2115-26. PMC: 4479154. DOI: 10.1158/1078-0432.CCR-14-1892. View

12.

Mollard A, Warner S, Call L, Wade M, Bearss J, Verma A . Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett. 2012; 2(12):907-912. PMC: 3254106. DOI: 10.1021/ml200198x. View

13.

Ghosh A, Secreto C, Knox T, Ding W, Mukhopadhyay D, Kay N . Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2009; 115(9):1755-64. PMC: 2832808. DOI: 10.1182/blood-2009-09-242719. View

14.

Ribatti D, Tamma R, Annese T . Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020; 13(6):100773. PMC: 7182759. DOI: 10.1016/j.tranon.2020.100773. View

15.

Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T . Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010; 107(3):1124-9. PMC: 2824310. DOI: 10.1073/pnas.0909333107. View

16.

Axelrod H, Pienta K . Axl as a mediator of cellular growth and survival. Oncotarget. 2014; 5(19):8818-52. PMC: 4253401. DOI: 10.18632/oncotarget.2422. View

17.

Ghosh A, Secreto C, Boysen J, Sassoon T, Shanafelt T, Mukhopadhyay D . The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2010; 117(6):1928-37. PMC: 3056640. DOI: 10.1182/blood-2010-09-305649. View

18.

Li Y, Tao Y, Gao S, Li P, Zheng J, Zhang S . Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. 2018; 36:209-220. PMC: 6197737. DOI: 10.1016/j.ebiom.2018.09.006. View

19.

Auyez A, Sayan A, Kriajevska M, Tulchinsky E . AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew. Cancers (Basel). 2021; 13(19). PMC: 8507788. DOI: 10.3390/cancers13194864. View

20.

Jayachandran M, Lugo G, Heiling H, Miller V, Rule A, Lieske J . Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biol Sex Differ. 2015; 6:2. PMC: 4345020. DOI: 10.1186/s13293-015-0021-2. View